PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Prev Res (Phila). Author manuscript; available in PMC 2011 December 1.
Published in final edited form as:
PMCID: PMC3058330
NIHMSID: NIHMS249482

Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models

Abstract

The incidence of anal cancer is increasing especially among HIV-infected persons in the HAART era. Treatment of this cancer is based upon traditional chemoradiotherapeutic approaches, which are associated with high morbidity, and of limited effectiveness for patients with high grade disease. The mammalian target of rapamycin (mTOR) pathway has been implicated in several human cancers, and is being investigated as a potential therapeutic target. In archival human anal cancers we observed mTOR pathway activation. To assess response of anal cancer to mTOR inhibition, we utilized two newly developed mouse models, one in which anal cancers are induced to arise in HPV16 transgenic mice, and the second a human anal cancer xenograft model. Using the transgenic mouse model, we assessed the preventative effect of rapamycin on neoplastic disease. We saw significant changes in the overall incidence of tumors, and tumor growth rate was also reduced. Using both the transgenic mouse and human anal xenograft mouse models, we studied the therapeutic effect of rapamycin on pre-existing anal cancer. Rapamycin was found to significantly slow, if not stop, the growth of both mouse and human anal cancers. As has been seen in other cancers, rapamycin treatment led to an activation of the MAPK pathway. These results provide us cause to pursue further the evaluation of rapamycin as a therapeutic agent in the control of anal cancer.

Introduction

Anal cancer is a disease of increasing incidence in the general population (1), and much more so amongst HIV infected men who have sex with men, particularly in the era of highly effective anti-HIV therapies, which have prolonged the life of HIV-infected persons (2). Anal cancer treatment has essentially remained static over the past two decades, and is often associated with a high degree of morbidity. Better clinical treatments are clearly needed for anal cancer patients, especially those with more advanced stages of disease, for whom the 5 year survival rates are dismally low (1).

Like cervical cancer, the vast majority of anal cancer is etiologically associated with high risk HPVs. As in cervical cancer, HPV16 is the most common genotype found in anal cancer, being present in 66% of these cancers (3). Of the HPV-associated cancers, however, anal cancer is one of the least well studied owing to the absence of laboratory model systems with which to pursue experiments. For example, there are no HPV-positive anal cancer cell lines yet reported in the literature. For this reason we established two new preclinical animal models for human anal cancer, providing us experimental platforms for better understanding the role of HPV in anal cancer and identifying novel approaches for preventing and/or treating this debilitating disease. Our first animal model for HPV-associated anal cancer was recently described (4) and is based in the use of HPV16 transgenic mice that have been used previously to develop mouse models for HPV-associated cervical (516) and head/neck (1719) cancers. In this mouse model, expression of HPV16 E6 and E7 oncogenes in the stratified epithelium of the anus synergized with the topically applied carcinogen, DMBA, to cause formation of a progressive neoplastic disease culminating in anal carcinoma. Biomarker expression (p16 and MCM7) paralleled that observed in human anal neoplastic disease (4). A second mouse model that we have developed is comprised of HPV16-positive human anal cancer xenografts passaged subcutaneously in immunodeficient (scid or nude) mice. This model is first described in the current study. Using these two mouse models we set out in this study to identify novel strategies for preventing and/or treating HPV-associated anal carcinomas. Because anal cancers in these mice arise on the exposed surfaces of the animals they can be easily monitored longitudinally, facilitating these studies. We focused our initial drug studies on rapamycin.

Rapamycin was originally isolated and identified as an antifungal agent (20), then discovered to have immunosuppressive activity (21). The molecular targets of rapamycin (TOR) were defined and the molecular pathway inhibited by rapamycin, the so-called mTOR pathway, characterized (for review see (22)). Rapamycin inhibits proliferation of mammalian cells (2325). Furthermore, the mTOR pathway that is targeted by rapamycin is induced in many cancers (26, 27) including squamous cell carcinomas of the cervix (28) and the head and neck region (2931), both sites of HPV-associated neoplasia. Preclinical studies demonstrated that many cell lines derived from such cancers or cancers arising in mice are also induced for the mTOR pathway and inhibited in their growth by rapamycin (for review see (32)) including in the case of squamous cell carcinomas of the head and neck (29, 3335). This has led to the clinical trials evaluating the efficacy of rapamycin or like drugs that inhibit the mTOR pathway in the treatment of human cancer (for review see (36)).

In this study we determined that the mTOR pathway was active in our two preclinical animal models for human anal cancer. This led us to evaluate whether rapamycin could prevent the onset of and/or treat anal cancers in these preclinical models. In both models rapamycin was reproducibly found to reduce significantly or stop altogether the growth of pre-existing anal tumors. Its effectiveness in preventing the onset of anal cancers was not significant; however, it did significantly prevent overall onset of tumors, which includes both benign and malignant lesions. These results provide the first preclinical evidence for the effectiveness of rapamycin in treating human anal cancer.

Materials and Methods

Mice

Generation of K14E6 and K14E7 mice has been previously described (37, 38). These mice were maintained on the inbred FVB/N genetic background. E6/E7 transgenic mice were generated by crossing K14E6 females with K14E7 males. Immunodeficient mice used for xenograft development included male and female SCID and Fox Nude mice obtained from Taconic and Harlan, respectively. All mice were kept in American Association for Accreditation of Laboratory Animal Care-approved McArdle Laboratory Cancer Center Animal Care Facility and studies with them were carried out in accordance to an approved animal protocol.

DMBA induced anal carcinogenesis

Anal carcinogenesis was achieved as previously described by weekly (20 week treatment period) topical treatment of DMBA (dimethylbenz[a]anthracene) to the anus at a dose of 0.12μmoles (4). The protocol was modified in that DMBA was dissolved in 60% acetone/40% DMSO (dimethylsulfoxide) vs 100% DMSO; this modification led to increased absorption of the carcinogen and increased tumor incidence compared to the original study. Mice were monitored weekly for appearance of overt tumors and change in size. Overt tumor size was measured at week 20 and the time of sacrifice (28th week) for all tumors. Tumor size was measured using calipers measuring the length and width of each tumor in mm.

Preventative treatment of E6/E7 transgenic mouse model with rapamycin

All K14E6/E7 mice began rapamycin treatment 120 days prior to the calculated sacrifice date based on DMBA protocol of 20 treatments followed by an 8 week hiatus which correlated to the 11th week of the DMBA treatment regiment. No mouse had an overt tumor present at the start of rapamycin treatment. Rapamycin treatment was achieved with 7.5mg 60 day slow release pellets (Innovative Research, Sarasota, FL) implanted subcutaneously resulting in a dose of 5mg/kg/day based upon the average mouse weight of 25 grams. Six of 27 tumor bearing mice were sacrificed early due to tumor size resulting in preventative rapamycin treatment ranging from 56 to 107 days. Matched K14E6/E7 control mice receiving no treatment also had no tumors at the 11th week of DMBA protocol. Mice were assigned to control or preventative arms at week 0 when DMBA treatments began.

Therapeutic treatment of E6/E7 transgenic mouse model with rapamycin

All K14E6/E7 mice began rapamycin treatment 60 days prior to the calculated sacrifice date based on DMBA protocol of 20 treatments followed by an 8 week hiatus, which correlated to the 20th (final) week of DMBA treatment regimen. All mice had an overt tumor present at the start of rapamycin treatment. Rapamycin treatment was achieved with 7.5mg 60 day slow release pellets (Innovative Research, Sarasota, FL) implanted subcutaneously resulting in a dose of 5mg/kg/day based upon the average mouse weight of 25 grams. Five of 12 tumor bearing mice were sacrificed early due to tumor size resulting in therapeutic rapamycin treatment ranging from 19 to 54 days. K14E6/E7 mice receiving no treatment that had also developed tumors at or before the 20th week of DMBA protocol were used as control mice (note this is a subset of the control mice for preventative treatment study). Mice were assigned to control or therapeutic arms at week 0 when DMBA treatments began.

Establishment of anal xenograft

After IRB approval, squamous cell anal carcinoma tissue was obtained by biopsy of the primary lesion from a 57 year old HIV-seropositive male without previous clinical therapy (radiation, chemotherapy, or surgery). Within 3 hours of tissue acquisition, the tissue was minced in sterile saline and injected into the subcutaneous plane of immunodeficient mice at the shoulder and hip areas as passage zero (P0). All tumor passages were monitored for tumor incidence and timing of first and last tumor onset (Table S1). Tumor passage was optimized at P4 by injecting 100μL minced tumor pieces in sterile saline mixed 1:1 with reduced growth factor Matrigel (BD Matrigel Basement Membrane Matrix, Growth Factor Reduced (GFR) Catalog #:354230).

Virus status of anal xenograft

P0 tissue at the time of harvest from immunodeficient mice was snap frozen. DNA and RNA from this tissue was isolated using Promega Wizard genomic DNA kit and Quigen RNAeasy minikit respectively. To detect HCV, RT-PCR was performed using 1μg template RNA and Invitrogen Superscript III One Step RT-PCR kit. PCR conditions were 1) 50°C for 30minutes, 2) 94°C for 4 minutes, 3) 94°C for 15 seconds, 4) 55°C for 30seconds, 5) 68°C for 1 minute, 6) repeat steps 3 to 5 for 40 cycles 7) final extension at 68°C for 5 minutes. HCV primers used were 5′primer (5′AAGCGTCTAGCCATGGCG3′) and 3′primer (5′CACTCGCAAGCACCCTATCA3′) at 0.2uM for a ~400bp product. To detect HIV, anal xenograft template DNA was subjected to nested PCR. Both PCR rounds (50uL) had final concentrations of 1x PCR buffer, 0.2mM dNTPs, 1.5mM MgCl2, and 0.02U Invitrogen Platinum Taq. In the first round of PCR, external primers were used with 100ng template DNA and were denatured at 94°C for 2 minutes followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 3 minutes 30 seconds with final extension at 72°C for 10 minutes. In the second round of PCR, 5μL of the external primer PCR product and primers to the HIV gag region were used under the same conditions except the extension step was shortened to 30 seconds from 3 minutes 30 seconds. External HIV primers used were 5′primer (5′GCGRCTGGTGAGTACGCC3′) and 3′primer (5′CACYAGCCATTGCTCTCC3′) at 0.2uM for a 3566 bp product. Gag region HIV primers used were 5′ primer (5′GATGACAGCATGTCAGGG3′) and 3′ primer (5′RGGAAGGCCAGATYTTCC3′) at 0.2uM for a 283bp product. To detect HPV, 100ng anal xenograft DNA was subjected PCR using JumpstartTaq with the same final concentrations as HIV detection and were denatured at 94°C for 4 minutes followed by 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 1 minute with final extension at 68°C for 5 minutes. HPV primers used were MY09 5′ primer (5′CGTCCMARRGGAWACTGATC3′) and MY11 3′primer (5′GCMCAGGGWCATAAYAATGG3′) at 0.2uM for a 448bp product. Final products for PCR reactions were run on a 2.5% agarose gel electrophoresis at 100V and stained with ethidium bromide. The HPV band was isolated by UV guidance, extracted using Quiagen gel extraction spin column protocol, and sequenced.

Analysis of HPV genome state

Total genomic DNA from P4 snap frozen tissue was isolated as previously described (39) such that high and low molecular weight DNAs were collected. DNA was incubated with NcoI or BamHI, at 37°C overnight and then run on a 0.8% agarose gel. Gels were denatured, neutralized, and DNA transferred to charged nylon membrane overnight. After UV crosslinking, the membrane was blocked and probed with radioactively labeled HPV16 probe.

Therapeutic treatment of anal xenograft mouse model with rapamycin

Tumors that developed in P4 and P5 xenografts were stratified into treatment and control arms based on tumor size such that each group had tumors with a similar range in size. Rapamycin treatment was achieved in P4 xenografts with 7.5mg 60 day slow release pellets (Innovative Research, Sarasota, FL) implanted subcutaneously resulting in a dose of 4.17mg/kg/day based upon the average mouse weight of 30 grams. Rapamycin treatment was performed on P5 xenografts by intraperitoneal (IP) injection of rapamycin dissolved in aqueous 5.2% polyethylene glycol and 5.2% Tween 80 for a dose of 5mg/kg/day for 5 days followed by 2 days without treatment. Control P5 mice were injected with vehicle only. Tumor size was measured twice weekly using calipers measuring the length and width of each tumor in mm. Both P4 and P5 mice were treated for a total of 4 weeks.

Histological Analysis

The anal canal tissue was fixed in 10% formalin, paraffin embedded, and serially sectioned at 5μm. Every 30th section was stained with H&E and histopathologically analyzed for normal/hyperplasia, papilloma, atypia, or carcinoma. Anal xenograft tumors were fixed and sectioned in the same method. The 5th section was H&E stained and confirmed to be squamous cell cancer on histopathology.

Immunohistochemistry, immunoflorescence and Western blot

Analyses were carried out as previously described (40). Primary antibodies were applied overnight at 4°C at the following concentrations in 2.5% horse serum for human xenograft tissues (1:200 p16INK4a, Neomarker; 1:200 K10 Sigma 8.6; 1:200 anti-MCM7, Neomarkers; 1:1000 K14, Covance; 1:100 pERK1/2, Cell Signaling). For detecting markers of mTOR pathway in both mouse and human tissues the following concentrations in 2.5% horse serum were used: 1:100 pS6 Ser235/236 (Cell Signaling); 1:50 pAkt Ser473 (Cell Signaling).

Statistical Analysis

Two-sided Wilcoxon rank-sum test was used to determine significant differences in tumor size, onset and growth rate. Two-sided Chi square test was used to determine differences in rates of disease in preventative and therapeutic treatment of rapamycin groups.

Results

The mTOR pathway is activated in anal cancers in our HPV16 transgenic mouse anal cancer model

As described in the introduction, there is evidence, based upon biomarker expression studies, that the mTOR pathway is activated in human squamous cell carcinomas including those arising in the cervix and head/neck region wherein HPVs can be an etiological factor. Also, Gutkind and colleagues have found the same pathway activated in squamous cell carcinomas arising in the oral cavity of mice. We previously generated a mouse anal cancer model in which HPV16 transgenic mice expressing the E6 and E7 oncogenes in stratified epithelium and treated topically with DMBA developed a progressive neoplastic anal disease culminating in squamous cell carcinoma (4). In the current study we asked if the mTOR pathway is active in the squamous cell carcinomas arising in this mouse model for anal cancer.

Nontransgenic and HPV16 transgenic (K14E6/E7) mice were treated topically with DMBA as described previously (4) but with a modification to the vehicle used to deliver DMBA (changed from 100% DMSO to 60%DMSO/40% acetone to improve adsorption of the carcinogen). This change led to an increased incidence of anal carcinomas both in the nontransgenic and HPV16 transgenic mice from 0% and 23%, respectively, observed in the original study (4) to 10% and 85%, respectively, in the current study. This allowed us to compare the activation of the mTOR pathway in both HPV-negative and HPV-positive anal carcinomas. Both phospho-AKT (pAKT) and phopho-S6 (pS6), two biomarkers commonly used for measuring activation of the mTOR pathway, scored uniformly positively in the squamous cell carcinomas of the mouse anus arising in the HPV16 transgenic mice (Fig. 1A). In contrast, the squamous cell carcinomas arising in the nontransgenic mice stained poorly for pAKT and non-uniformly for pS6. In normal anal epithelium both pAKT and pS6 were largely restricted in their detection to the more terminally differentiated compartment (Fig 1A). These biomarkers results are consistent with the mTORC1 pathway being activated in these cancers, though at least one of these markers, pAKT, is also a marker for mTORC2 pathway. These data provided us cause to assess whether an activated mTORC1 pathway is required for the development and/or maintenance of the cancer state in this mouse model for anal carcinoma, by monitoring the effects of rapamycin in this mouse model. Because the mTOR pathway appears more uniformly activated in the anal cancers arising in the HPV16 transgenic mice (Fig 1A), and because the majority of anal cancers in humans are HPV-positive, we focused our further analysis on anal carcinogenesis in the context of the HPV16 transgenic mice.

Figure 1
Influence of mTOR pathway on anal carcinogenesis in HPV16 transgenic mice

Preventative rapamycin treatment decreases tumor incidence and growth

To assess whether inhibition of the mTOR pathway prevents tumors from arising in our mouse model for HPV-associated anal cancer, we gave K14E6/E7 mice the drug rapamycin, using continuous release pellets that delivered the drug at 5mg/kg/day, beginning at the 11th week of the 20-week topical DMBA treatment (Fig. 1B: preventative). The 11th week of DMBA-treatment was chosen because no overt tumors had yet arisen at that time in the DMBA treatment. After 20 weeks of DMBA treatment, mice were held an additional 8 weeks, at which time tumors were harvested for histopathological analysis. Rapamycin was given to the mice throughout the remaining time course of the experiment, i.e. from week 11to the week 28 endpoint. Time of onset of overt tumors, tumor growth rates, tumor size and tumor grade were compared between the cohort of mice given rapamycin to a control cohort not given the drug (Table 1). Rapamycin treated K14E6/E7 mice had significantly decreased overt tumor incidence (overt tumors include papillomas, atypia and carcinomas) compared to control K14E6/E7 mice (73% vs. 100%, p=0.01); though, on histological analysis, the difference in carcinoma incidence (70% in rapamycin-treated vs 85% in control) was not significant (p=0.22) (Table 1). While the time of tumor onset was only slightly delayed in the rapamycin-treated cohort, the tumors that did develop in the rapamycin-treated cohort were smaller both at the 20th week of DMBA-treatment and at the 28 week endpoint. These decreases in tumor size translated to a nearly three-fold reduction in tumor growth rate in the rapamycin-treated mice (Table 1, Fig 1C), from on average 1.5 mm/week in the control group down to 0.6 mm/week in the rapamycin-treated group. This 2.5 fold decrease in tumor growth rate approached the 95% confidence limit of significance (p=0.08).

Table 1
Preventative Treatment of Mouse Anal Cancer

Therapeutic rapamycin treatment significantly lowered tumor growth rate in transgenic HPV mice

To assess the effect of rapamycin on already established tumors, K14E6/E7 mice treated with DMBA for 20 weeks that had all developed tumors by that time point, were treated with rapamycin, starting at the last week of DMBA treatment, for the remaining 8 weeks, until the 28 week endpoint of the study (Fig. 1B: therapeutic), at which time tumors were harvested. These mice were compared to a cohort of DMBA-treated mice not exposed to rapamycin, who also bore tumors at the 20 week time point. There was no significant difference in the histological grade of tumor in the two groups of mice at the 28 week endpoint (Table 2). However, tumor size at endpoint was significantly lower in the rapamycin-treated K14E6/E7 mice (Table 2) translating to an approximate three fold decreased tumor growth rate compared to the control mice (Table 2, Fig. 1D), from on average 1.7 mm/week in the control mice down to 0.5 mm/week in the rapamycin-treated mice. This 3.4-fold difference was significant (p=0.01) and was similar to what was observed in the mice treated with rapamycin in the prevention trial (Table 1, Fig. 1C). Together, the results of these prevention and therapeutic trials in DMBA-treated K14E6/E7 mice indicate that rapamycin could reduce growth of mouse anal tumors.

Table 2
Therapeutic Treatment of Mouse Anal Cancer

Human anal cancers display evidence for activated mTOR

Given the data from our mouse anal cancer study, we wanted to learn whether the mTOR pathway is activated in human anal cancers. With IRB approval, we identified 10 patients who were treated for anal cancers at the University of Wisconsin Hospitals for which the presence of squamous cell carcinoma could be confirmed histopathologically in paraffin embedded biopsies taken prior to chemoradiation. These were subjected to phospho-S6 specific immunohistochemistry. All the cancers showed staining for pS6 throughout the malignant lesions (shown in Fig. 2A–C are three representative cancers). In contrast, in nearby normal anal epithelium, cells staining positively for phospho-S6 were limited to the more superficial portion of the spinous layer with some weak, occasional staining in the basal/parabasal compartment (Fig 2D). These findings provided evidence that in human anal cancers, the mTOR pathway may be activated.

Figure 2
Detection of pS6, a marker for an active mTOR pathway, in archival human anal cancers

Establishment of a human anal cancer xenograft that is HPV16-positive and retains human anal cancer characteristics

To address the potential effects of rapamycin on human anal cancer, we established anal cancer xenografts from human squamous cell anal cancer tissue. A biopsy from a patient presenting with anal cancer was acquired under IRB approval from the University of Wisconsin Hospital, transferred to McArdle Laboratory for Cancer Research on campus and injected subcutaneously into the flanks of SCID mice. The cancer grew as tumor xenografts at multiple sites and could be passaged multiple times (to date it has been passaged 6 times). The efficiency of passaging (i.e. time of initial onset of tumors and efficiency of tumor growth) was positively affected by mixing the tumor with Matrigel and it could grow in both SCID and Nude mouse strains (Table S1). Histologically, the tumor xenograft retained over passaging the histopathological characteristics of being a poorly differentiated squamous carcinoma (Fig. 3A). It displayed strong positive staining for MCM7, and p16 (Fig. 3B). It stained positively for Keratin 14 but not Keratin 10, consistent with its poorly differentiated characteristics (data not shown). To assess whether the mTOR pathway was activated, the xenograft was scored for pAKT and pS6 and found to be positive for both (Fig. 3B). The P0 xenograft was initially determined to be HPV16-positive (data not shown), based upon sequence analysis of a PCR amplimer generated in a PCR reaction on the xenograft-derived DNA using the MY9/11 primer pair (see methods). This primer pair is routinely used to detect common anogenital HPV genotypes in clinical samples. Subsequent passages of the xenograft retained HPV positive status by PCR. Southern analysis of P4 xenograft derived total genomic DNA confirmed that the cancer is HPV16 positive, with a hybridization pattern consistent with the HPV16 DNA being integrated (Fig. 3C). The P0 xenograft was also screened by PCR and found to be negative for HIV and HCV (data not shown). The patient was previously screened to be positive for both of these pathogens.

Figure 3
Influence of mTOR pathway on human anal cancer xenografts

Human anal xenograft tumor growth rates were significantly lower upon rapamycin treatment

To assess the effect of inhibiting the mTOR pathway on growth of human anal cancers, mice bearing tumors that developed from P4 anal cancer xenografts were placed into control or rapamycin-treatment groups such that the average tumor size at the outset of rapamycin treatment was not significantly difference between the two groups. In the initial experiment mice were given rapamycin using slow release pellets, providing a dose of 4.17mg/kg/day. Tumor size was measured using calipers weekly for four weeks. The tumors in the mice treated with rapamycin had lower tumor growth rates (avg. = 0.24 ±0.3 mm/week) compared to that in the control group (avg. = 0.74 mm/week) (Table 3, Fig. 3D: left graph). This difference was highly significant (p < 0.01).

Table 3
Therapeutic Treatment of Human Anal Cancer Xenografts

Prior studies used in mice with oral cancers (34) had used a slightly higher dose of rapamycin 5mg/kg/day delivered IP. We therefore repeated the experiment in passage 5 tumor xenografts using this higher dose and alternative delivery method. In this experiment, the tumors were more completely inhibited in their growth (Table 3, Fig 3D: right graph), showing on average a slight negative growth (−0.02 mm/week) during the 4-week treatment period compared to the tumors in the paired untreated group (0.74 mm/week). This complete block in tumor growth was also highly significant (p < 0.01). These results demonstrate that an HPV16-positive human anal cancer, carried as a xenograft in mice, is inhibited significantly in its growth by rapamycin.

ERK is activated by rapamycin treatment

Prior studies have demonstrated that the MAPK pathway can be activated by rapamycin treatment of tumors (41). As such activation of the MAPK pathway provides a useful readout for the rapamycin activity. To learn if the MAPK pathway was activated in the human xenografts treated with rapamycin, we monitored levels of phosphorylated ERK (p-ERK) by immunoblot analysis. We found a strong induction of pERK in the human anal cancer xenografts treated with rapamycin (Fig 4).

Figure 4
The MAPK pathway is activated in human anal cancer xenografts treated with rapamycin

Discussion

In this study we demonstrate that both mouse and human anal tumors are activated in the mTOR pathway and are significantly reduced in their growth rates upon administration of rapamycin. These results provide preclinical data to support the use of mTOR inhibitors in the therapeutic treatment of human anal cancers. Our prevention trial in the context of the mouse anal cancer model did not demonstrate efficacy at the level of preventing frank cancer, though overall tumor incidence and growth was reduced by early onset treatment with rapamycin prior to onset of overt tumors.

The utility of mTOR inhibitors in the clinic has been found to be maximal when these inhibitors are combined with other anti-cancer treatments. This may reflect the fact that, although mTOR inhibitors can induce cell death, they primarily act as cytostatic agents (42, 43). In addition, rapamycin has been observed to induce MAPK in some cancers, and this can negatively effect its therapeutic effect as evidenced by the fact that drugs that inhibit MAPK can synergize with rapamycin to cause further reduction in tumor growth/persistence (41). Consistent with these prior observations, we observed induction of activated ERK (Fig. 4). Rapamycin also has been found to act as a radiation-sensitizer in many cancers (4447). These studies with other cancer types and our own observations (Fig. 4) point to the value of pursuing further studies using our preclinical animal models for anal cancer to identify combinatorial therapeutic regimens including the use of mTOR inhibitors that could have greater effect in treating human anal cancer with reduced morbidity associated with standard of care treatments available today.

For our therapeutic trials on the human anal cancer xenograft, we used two modes of rapamycin delivery, one using a slow release pellet that, based upon the weight of the recipient animals, should have delivered ~4.2 mg/kg/day or rapamycin, the other mode was 5x weekly IP injections at a dose of 5 mg/kg/treatment. While both modes of delivery were effective in decreasing the growth rates of the xenografts, clearly the latter was more effective. Whether this reflects differences in maximum and/or trough levels of drug is unclear; however, the latter clearly has importance in other mouse models (48).

In the context of these studies we developed a new human, HPV-positive, anal cancer xenograft model. This animal model provides a powerful laboratory experimental system in which to assess the role of HPV and cellular genes/pathways in this poorly studied human cancer. As such it complements the utility of our previously described mouse anal cancer model for HPV-associated human anal cancer. That both the mouse anal cancer and human anal cancer mouse models respond similarly to rapamycin provides further validation of the former model.

Supplementary Material

Acknowledgments

We thank Dawn Dudley of Dr. David O’Connor’s Lab and Israr Ansari of Dr. Rob Striker’s lab, both at UW-Madison, for help with PCR screening for HIV and HCV, respectively. This study was supported by NIH grants (R01 DE017315, U01 CA141583) funded to PFL. MKS was supported by a NIH training grant (NIH/NCI T32 CA090217) for clinical fellows.

References

1. Ries EA. SEER Cancer Statistics Review 1975–2005. Bethesda, MD: National Cancer Institute;
2. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36. [PubMed]
3. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124(10):2375–83. [PubMed]
4. Stelzer M, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF. A Mouse Model for Human Anal Cancer. Cancer Prevention Research. 2010 in press. [PMC free article] [PubMed]
5. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res. 2003;63(23):8173–80. [PubMed]
6. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A. 2005;102(7):2490–5. [PubMed]
7. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003;63(16):4862–71. [PubMed]
8. Balsitis S, Dick F, Dyson N, Lambert PF. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res. 2006;66(19):9393–400. [PMC free article] [PubMed]
9. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 2008;68(23):9928–34. [PMC free article] [PubMed]
10. Chung SH, Lambert PF. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A. 2009;106(46):19467–72. [PubMed]
11. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009;69(10):4407–14. [PMC free article] [PubMed]
12. Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010;70(7):2924–31. [PMC free article] [PubMed]
13. Shai A, Nguyen ML, Wagstaff J, Jiang YH, Lambert PF. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP. Oncogene. 2007;26(23):3321–8. [PMC free article] [PubMed]
14. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res. 2008;68(8):2622–31. [PMC free article] [PubMed]
15. Shai A, Pitot HC, Lambert PF. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010;70(12):5064–73. [PMC free article] [PubMed]
16. Shin MK, Balsitis S, Brake T, Lambert PF. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 2009;69(14):5656–63. [PMC free article] [PubMed]
17. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A. 2006;103(38):14152–7. [PubMed]
18. Strati K, Lambert PF. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res. 2007;67(24):11585–93. [PMC free article] [PubMed]
19. Jabbar S, Strati K, Shin MK, Pitot HC, Lambert PF. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology. 2010 [PMC free article] [PubMed]
20. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28(10):721–6. [PubMed]
21. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55(1):48–51. [PubMed]
22. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324–37. [PMC free article] [PubMed]
23. Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology. 1991;72(4):544–9. [PubMed]
24. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54(4):903–7. [PubMed]
25. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76(3):412–7. [PubMed]
26. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol. 2008;128(4):980–7. [PubMed]
27. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596–603. [PubMed]
28. Faried LS, Faried A, Kanuma T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog. 2008;47(6):446–57. [PubMed]
29. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007;67(5):2160–8. [PubMed]
30. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005;65(21):9953–61. [PubMed]
31. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res. 2007;13(17):4964–73. [PubMed]
32. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008;6(Suppl 5):S1–S20. quiz S1–S2. [PubMed]
33. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2009;2(1):27–36. [PubMed]
34. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res. 2009;69(10):4159–66. [PubMed]
35. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2008;62(2):305–13. [PubMed]
36. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol. 2009;36 (Suppl 3):S46–58. [PubMed]
37. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol. 1996;70(3):1873–81. [PMC free article] [PubMed]
38. Song S, Pitot HC, Lambert PF. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol. 1999;73(7):5887–93. [PMC free article] [PubMed]
39. Holmgren SC, Patterson NA, Ozbun MA, Lambert PF. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol. 2005;79(7):3938–48. [PMC free article] [PubMed]
40. Balsitis SJ, Sage J, Duensing S, Munger K, Jacks T, Lambert PF. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol. 2003;23(24):9094–103. [PMC free article] [PubMed]
41. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–74. [PubMed]
42. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. 2001;61(8):3373–81. [PubMed]
43. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120(6):747–59. [PubMed]
44. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5(5):1183–9. [PubMed]
45. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66(20):10040–7. [PubMed]
46. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res. 2009;15(2):589–96. [PubMed]
47. Nagata Y, Takahashi A, Ohnishi K, et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol. 37(4):1001–10. [PubMed]
48. Granville CA, Warfel N, Tsurutani J, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res. 2007;13(7):2281–9. [PubMed]